1 The impact of immunosuppression on chronic kidney disease in people living with HIV; the D:A:D study. Ryom L, Lundgren JD, Reiss P, Ross M, Kirk O, Fux CA, Morlat P, Fontas E, Smith C, De Wit S, d'Arminio Monforte A, El Sadr W, Hatleberg C, Phillips A, Sabin C, Law M, Mocroft A; D:A:D Study Group.
J Infect Dis. 2020:jiaa396. doi: 10.1093/infdis/jiaa396. Epub ahead of print. Abstract

2 Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D: A: D study. Petoumenos K, Kuwanda L, Ryom L, Mocroft A, Reiss P, De Wit S, Pradier C, Phillips A, Hatleberg CI, d'Arminio Monforte A, Weber R, Sabin CA, Lundgren J, Law MG; D:A:D Study group.
J Acquir Immune Defic Syndr. 2020. Abstract

3 Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. Dietrich LG, Barceló C, Thorball CW, Ryom L, Burkhalter F, Hasse B, Furrer H, Weisser M, Steffen A, Bernasconi E, Cavassini M, de Seigneux S, Csajka C, Fellay J, Ledergerber B, Tarr PE.
Clin Infect Dis. 2020;70(5):890-897. Abstract